Compare Stocks → A new way to collect income from stocks (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEOOTCMKTS:EDTXFOTCMKTS:HBPCF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.26+2.2%$7.31$2.83▼$9.01$89.16M1.49441,766 shs1.21 million shsEDTXFSpectral Medical$0.35+6.0%$0.35$0.17▼$0.50$97.91M0.8120,571 shs6,642 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$31.59M-0.1N/AN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+0.63%-57.64%-56.66%-31.98%-0.31%EDTXFSpectral Medical+7.48%+3.57%-2.72%-11.69%+51.45%HBPCFHelix BioPharma0.00%0.00%0.00%-5.03%-5.81%It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here <<MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.091 of 5 stars3.51.00.04.52.23.30.6EDTXFSpectral MedicalN/AN/AN/AN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.001,004.29% UpsideEDTXFSpectral MedicalN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest ONT, ABEO, EDTXF, ARIX, and HBPCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M25.47N/AN/A$0.60 per share5.43EDTXFSpectral Medical$1.18M82.98N/AN/A($0.04) per share-8.79HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)EDTXFSpectral Medical-$11.60M-$0.04N/A∞N/A-974.16%N/A-210.60%5/10/2024 (Estimated)HBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)Latest ONT, ABEO, EDTXF, ARIX, and HBPCF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023EDTXFSpectral MedicalN/A-$0.02-$0.02-$0.02N/A$0.27 million3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AEDTXFSpectral MedicalN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15EDTXFSpectral MedicalN/A0.400.37HBPCFHelix BioPharmaN/A1.461.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%EDTXFSpectral MedicalN/AHBPCFHelix BioPharmaN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%EDTXFSpectral Medical1.50%HBPCFHelix BioPharma7.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableEDTXFSpectral Medical29278.64 million274.46 millionNot OptionableHBPCFHelix BioPharma9229.44 million212.00 millionNot OptionableONT, ABEO, EDTXF, ARIX, and HBPCF HeadlinesSourceHeadlineHelix Dusk Luxe Mattress Review 2024: A Comfortable Pillow-Top Bedcnet.com - April 17 at 5:42 PMHelix BioPharma Corp. Reports Voting Resultsfinance.yahoo.com - January 22 at 12:58 PMHelix BioPharma Corp. Announces Fiscal 2024 First Quarter Resultsfinance.yahoo.com - December 14 at 7:26 PMHelix BioPharma Corp HBPmorningstar.com - November 28 at 11:29 PMHelix Biopharma GAAP EPS of -C$0.03msn.com - October 27 at 9:54 PMHelix BioPharma Corp. Announces Fiscal 2023 Year-End Resultsfinance.yahoo.com - October 27 at 9:54 PMHelix BioPharma Corp. (HBP)uk.investing.com - September 14 at 6:01 PMHELIX BIOPHARMA CORP (HBPCF) stock forecast and price targetfinance.yahoo.com - June 29 at 2:20 PM15 Best Memorial Day Mattress Sales You Can Shop Right Now: Nectar, Helix, Tempur-Pedic and Moreetonline.com - May 24 at 6:58 PMHelix Energy Up on BP Spill Contractthestreet.com - May 14 at 7:33 PMHelix Biopharma Corp. Announces Fiscal 2023 Second Quarter Resultsfinance.yahoo.com - March 15 at 6:50 PMReflections on the Double Helix’s Platinum Anniversarygenengnews.com - February 2 at 8:59 AMIs Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - January 31 at 7:31 AMHelix BioPharma appoints R&D headseekingalpha.com - September 3 at 9:46 PMProactive news headlines including Shell, Maverix Metals, Helix BioPharma, Wellteq Digital Health and Trees Corpbenzinga.com - September 2 at 3:43 PMHelix Biopharma Corp. Announces Appointment of New Chief Financial Officerfinance.yahoo.com - May 18 at 9:52 AMHelix BioPharma appoints Artur Gabor as its new CEO; adds three new board membersca.proactiveinvestors.com - April 18 at 2:01 PMHelix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscriptionfinance.yahoo.com - April 13 at 6:17 PMHelix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscriptionfinance.yahoo.com - April 13 at 6:17 PMHelix Biopharma GAAP EPS of -$0.01seekingalpha.com - March 18 at 7:10 AMHelix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Boardfinance.yahoo.com - March 16 at 10:32 AMHelix Biopharma Corp. (HBPCF)nasdaq.com - January 28 at 11:33 PMHelix BioPharma Corp. Reports Voting Results and Appointment of New Board Directorfinance.yahoo.com - January 28 at 6:33 PMHelix Biopharma: Fiscal Q1 Earnings Snapshottimesunion.com - December 15 at 8:59 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesDisney Stock Catches 3 Upgrades In a Single WeekMarch 28, 2024 10:27 AMView Disney Stock Catches 3 Upgrades In a Single Week5 Small-Cap Energy Stocks Surged in Price and Volume on FridayApril 15, 2024 7:50 AMView 5 Small-Cap Energy Stocks Surged in Price and Volume on FridayMarketBeat Week in Review – 3/25-3/29March 30, 2024 7:00 AMView MarketBeat Week in Review – 3/25-3/293 Companies Buying Back Stock Before New HighsApril 1, 2024 6:05 AMView 3 Companies Buying Back Stock Before New HighsGold Rush: Exploring 5 Sector Giants Amidst Soaring PricesApril 4, 2024 6:10 AMView Gold Rush: Exploring 5 Sector Giants Amidst Soaring PricesAll Headlines Company DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Spectral MedicalOTCMKTS:EDTXFSpectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.